Home PR Newswire
Tuesday, April 21, 2026
29.7
C
Bengaluru
Hot topics
Blinkit, Zepto, Instamart: Who Will Own India’s At‑Home Diagnostics Market?
India’s diagnostics market is undergoing a quiet but profound...
Digital Therapeutics: New Frontiers in Healthcare
“If we look at major trends, people are living longer, on average, so there’s a rise in chronic diseases associated with aging. Meanwhile, healthcare workers are in short supply, and physicians and nurses do not have enough time for patients. Yet everyone has powerful computers in their pockets that give them access to technology, education, and information. Put all that together, and it’s the perfect moment for digital solutions to come to the market, change behavior, and enhance health outcomes at scale”
- Bozidar Jovicevic, Global head of Digital Therapeutics, Sanofi
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Careers in Medical Device Companies
Key Insights
Thermo Fisher Scientific leads the industry with $42.88 billion...
IQVIA Sponsors Race for 7 to Commemorate World Rare Disease Day
“IQVIA is delighted to be associated for the fourth consecutive year as the main sponsor of Race for 7. While rare diseases, by virtue of their definition, affect relatively fewer number of patients, the overall number of rare disease patients is large enough to warrant more focused attention."
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
Hot topics
Opportunities for Indian Pharma
Articles by Bhaskar Chakravorty, Hanno Wolfram, K. Hariram, Krishna Singh, Shreenivas S, Chandan Kumar and Salil Kallianpur
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
How Did Telma Become a 1000+ Cr Brand?
The untold story of Glenmark's phenomenal success in building...
Can Servier Hit the INR 1000 Cr Mark with Drugs + Diagnostics GTM?
In an industry often defined by blockbuster-driven strategies and...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
Newsletter
Get important news delivered directly to your inbox and stay connected!